Corient Private Wealth
VKTX icon

Corient Private Wealth’s Viking Therapeutics VKTX Stock Holding History

Corient Private Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
27,463
+5,394
+24% +$174K ﹤0.01% 1770
2026
Q1 		$716K Buy
22,069
+4,911
+29% +$158K ﹤0.01% 1835
2025
Q4 		$604K Buy
17,158
+1,233
+8% +$43.7K ﹤0.01% 1772
2025
Q3 		$419K Buy
15,925
+2,933
+23% +$87.5K ﹤0.01% 1913
2025
Q2 		$344K Sell
12,992
-224
-2% -$5.9K ﹤0.01% 1915
2025
Q1 		$319K Buy
13,216
+797
+6% +$25.2K ﹤0.01% 1818
2024
Q4 		$500K Sell
12,419
-396
-3% -$22.6K ﹤0.01% 1617
2024
Q3 		$811K Buy
12,815
+486
+4% +$28.5K ﹤0.01% 1507
2024
Q2 		$654K Sell
12,329
-9,971
-45% -$654K ﹤0.01% 1508
2024
Q1 		$1.83M Buy
22,300
+828
+4% +$36.8K ﹤0.01% 1062
2023
Q4 		$400K Buy
+21,472
New +$281K ﹤0.01% 1727

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Corient Private Wealth's VKTX Position: Q2 2026 in Review

Corient Private Wealth increased its Viking Therapeutics (VKTX) stake by 24% in Q2 2026, buying an estimated $174K and bringing the position to 27,463 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1770.

Corient Private Wealth first reported a position in VKTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.83M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Corient Private Wealth held 27,463 shares of Viking Therapeutics worth $1.07M as of Q2 2026.
  • Corient Private Wealth bought 5,394 Viking Therapeutics shares in Q2 2026, an estimated $174K.
  • Viking Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1770 holding.
  • Corient Private Wealth first reported a position in Viking Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Corient Private Wealth's Viking Therapeutics position peaked at $1.83M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.